© 1998 American Heart Association, Inc.
Original Contributions |
Thrombin Stimulates Vascular Smooth Muscle Cell Polyamine Synthesis by Inducing Cationic Amino Acid Transporter and Ornithine Decarboxylase Gene Expression
From the Houston VA Medical Center (W.D., L.L., K.J.P., A.I.S.) and the Departments of Medicine (W.D., L.L., A.I.S.) and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex.
Correspondence to William Durante, PhD, Houston VA Medical Center, Building 109, Room 128, 2002 Holcombe Blvd, Houston, TX 77030.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Thrombin, a serine protease, is a potent mitogen for vascular smooth muscle cells (SMCs), but its mechanism of action is not known. Since L-ornithine is metabolized to growth-stimulatory polyamines, we examined whether thrombin regulates the transcellular transport and metabolism of L-ornithine by vascular SMCs. Treatment of SMCs with thrombin initially (0 to 2 hours) decreased L-ornithine uptake, whereas longer exposures (6 to 24 hours) progressively increased transport. Kinetic studies indicated that thrombin-induced inhibition was associated with a decrease in affinity for L-ornithine, whereas stimulation was mediated by an increase in transport capacity. Thrombin induced the expression of both cationic amino acid transporter (CAT)-1 and CAT-2 mRNA. Furthermore, thrombin stimulated L-ornithine metabolism by inducing ornithine decarboxylase (ODC) mRNA expression and activity. The stimulatory effect of thrombin on both L-ornithine transport and ODC activity was reversed by hirudin, a thrombin inhibitor, and was mimicked by a 14–amino acid thrombin receptor–activating peptide. Thrombin also markedly increased the capacity of SMCs to generate putrescine, a polyamine, from extracellular L-ornithine. The thrombin-mediated increase in putrescine production was reversed by NG-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by
-difluoromethylornithine (DFMO), an ODC inhibitor.
DFMO also inhibited thrombin-induced SMC proliferation. These results
demonstrate that thrombin stimulates polyamine synthesis by inducing
CAT and ODC gene expression and that thrombin-stimulated SMC
proliferation is dependent on polyamine formation. The ability of
thrombin to upregulate L-ornithine transport and direct its
metabolism to growth-stimulatory polyamines may contribute
to postangioplasty restenosis and atherosclerotic lesion
formation.
Key Words: thrombin • L-ornithine • polyamine • proliferation
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Thrombin is a multifunctional serine protease that is activated at sites of blood vessel injury.1 2 Apart from its central role in hemostasis and thrombosis, thrombin has been implicated in the pathogenesis of postangioplasty restenosis and atherosclerosis.3 Numerous studies have demonstrated that thrombin is a potent mitogen for vascular smooth muscle cells (SMCs).4 5 6 7 Thrombin stimulates the release of growth factors from platelets and vascular cells and directly induces SMC proliferation.4 5 6 7 8 9 However, the mechanism by which thrombin mediates SMC growth is not known. Recent studies indicate that the formation of polyamines plays an integral role in the mitogenic response of vascular SMCs. SMC proliferation is preceded by increases in cellular polyamine content, and inhibition of polyamine synthesis prevents cell growth.10 11 12 Furthermore, the exogenous addition of polyamines to SMCs stimulates DNA synthesis.10
The polyamines putrescine, spermidine, and spermine are naturally occurring organic cations found in all eukaryotic cells. Putrescine is generated from the cationic amino acid L-ornithine via a decarboxylation reaction catalyzed by the enzyme ornithine decarboxylase (ODC), whereas the successive polyamines, spermidine and spermine, are formed by the sequential transfer of an aminopropyl group from S-adenosylmethionine.13 Induction of ODC activity and polyamine synthesis correlate with cell growth in various experimental conditions. Both arterial injury–induced and platelet-derived growth factor (PDGF)-mediated SMC proliferation is associated with a striking increase in ODC activity.10 12 14 Moreover, pharmacological blockade of ODC inhibits both arterial injury–mediated and PDGF-mediated SMC proliferation, indicating that ODC activity is essential for SMC growth.10 12 15
Although ODC activity is often believed to be rate-limiting in the
polyamine biosynthetic pathway, recent studies indicate that
L-ornithine availability also plays a crucial role in
regulating polyamine synthesis. The steady-state intracellular level of
L-ornithine markedly influences polyamine formation and DNA
synthesis in neoplastic cells.16 17 In addition,
we have demonstrated that PDGF and lysophosphatidylcholine-induced
polyamine synthesis and vascular SMC mitogenesis are dependent on the
transcellular transport of
L-ornithine.12 18 The transport of
cationic amino acids, such as L-ornithine, by vascular SMCs
is mediated by the system y+
carrier.19 20 This particular transport system is
characterized by its high affinity for cationic amino acids, its
Na+ independence, and the stimulation of
transport by substrate on the opposite (trans) side of the
membrane.21 Recently, the proteins responsible
for the activity of the system y+ carrier have
been cloned and designated as cationic amino acid transporter (CAT)-1,
CAT-2, and CAT-2A.22 23 24 25 Both CAT-1 and CAT-2 are
high-affinity (Km, 
100 µmol/L)
low-capacity transporters for cationic amino acids, whereas CAT-2A is
an alternate splice variant of CAT-2 that possesses low affinity but
high transport capacity.23 24 25 In a previous
study, we found that vascular SMCs express mRNA for both the
high-affinity transporters, CAT-1 and CAT-2, but do not express message
for CAT-2A.12
Since polyamines play a critical role in mediating cell growth, the present study examined whether thrombin regulates polyamine synthesis. We now report that thrombin coordinately induces the gene expression of CAT proteins and ODC, resulting in markedly increased production of polyamines by vascular SMCs. In addition, we show that thrombin-stimulated SMC proliferation is dependent on polyamine synthesis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
Fetal calf serum, L-ornithine, trichloroacetic acid, penicillin, streptomycin, SDS, EDTA, elastase, collagenase, trypsin, hirudin, pyridoxal-5-phosphate, ammonium hydroxide, chloroform, formamide, methanol, Triton X-100, Tris, TES, HEPES, ninhydrin spray, and thin-layer chromatography plates (silica gel-25) were purchased from Sigma Chemical Co; actinomycin D, ribonuclease A, and ribonuclease T1 were from Boehringer Mannheim; human
-thrombin was from
US Biochemicals; thrombin receptor–activating peptide (TRAP
[SFLLRNPNDKYEPF]) was synthesized at the Baylor College of Medicine
Protein Chemistry Core Facility (Houston, Tex); plasmin was from Kabi;
MEM was from ICN Biomedicals; guanidine isothiocyanate and CsCl were
from GIBCO; DTT and the Bradford protein assay were from Bio-Rad
Laboratories; GAPDH cDNA and RNA molecular weight markers were from
Ambion Inc; ODC cDNA was from American Type Culture Collection;
bicinchoninic acid protein assay was from Pierce; Gene Screen Plus
membranes were from New England Nuclear; -difluoromethylornithine
(DFMO) was generously provided by Dr Ekkhardt H.W. Bohme (Hoechst
Marion Roussel, Cincinnati, Ohio);
[3H]L-ornithine (55 Ci/mmol) was
from American Radiolabeled Chemicals; and
[1-14C]L-ornithine (55 mCi/mmol)
and [-32P]UTP (400 Ci/mmol) were from
Amersham Corp.
SMC Culture
Vascular SMCs were isolated by elastase and
collagenase digestion of thoracic aortas obtained from
adult 12-week-old male rats and characterized by morphological and
immunological criteria.26 Cells were cultured
serially in MEM containing Earle's salts, 5.6 mmol/L glucose,
2 mmol/L L-glutamine, 20 mmol/L TES-NaOH, 20
mmol/L HEPES-NaOH, 100 U/mL penicillin, and 100 U/mL streptomycin.
Subcultured strains were used between passages 6 to 28. When cells
reached confluence, the culture media were replaced with serum-free
media containing BSA (0.1%) for 24 hours and then exposed to the
various treatment regimens.
L-Ornithine Transport
L-Ornithine transport was determined by measuring
the influx of radiolabeled L-ornithine into SMCs, as
previously described.20 Cells grown on 12-well
plates were washed with HEPES buffer (140 mmol/L choline chloride,
5.0 mmol/L KCl, 1.0 mmol/L MgCl2,
0.9 mmol/L CaCl2, 5.6 mmol/L
D-glucose, and 25 mmol/L HEPES, pH 7.4) and then
incubated for 45 seconds in 0.5 mL HEPES buffer containing
[3H]L-ornithine (50 µmol/L,
1 µCi). Transport activity was terminated by aspirating the media and
rapidly washing the cells with ice-cold HEPES buffer. Cells were
allowed to dry, and the cell-associated radioactivity was extracted
with 500 µL of 0.2% SDS in 0.2N NaOH and then assayed by liquid
scintillation spectrometry (Tri-Carb liquid scintillation
analyzer, model 1900 TR, Packard). Protein in the NaOH extracts
was measured using the bicinchoninic acid method with serum
albumin as the standard.27 To correct for
nonspecific uptake or binding to the cell surface, cells were incubated
in parallel wells with HEPES buffer containing 10 mmol/L unlabeled
L-ornithine, the fraction of the radioactivity of the cells
was determined, and this fraction was then subtracted from each data
point.
ODC Assay
ODC activity was determined by measuring the release of
14CO2 from
[1-14C]L-ornithine, as previously
described.28 SMCs were harvested in ice-cold Tris
buffer (20 mmol/L Tris, 0.1 mmol/L EDTA, 2 mmol/L DDT,
and 0.1 mmol/L pyridoxal-5-phosphate, pH 7.4), sonicated, and
centrifuged at 14 000g for 20 minutes at 4°C. The
supernatant (soluble fraction) was collected and stored at -70°C
until use. The reaction mixture (400 µL) contained 250 µmol/L
[14C]L-ornithine (0.25 µCi) and
0.2 mg soluble protein in Tris buffer. Incubations were carried out in
stoppered glass tubes for 2 hours at 37°C. The
14CO2 liberated by the
decarboxylation of L-ornithine was trapped on a piece of
filter paper impregnated with 2N NaOH, which was suspended above the
reaction mixture. The reaction was stopped by the addition of
trichloracetic acid (10% final concentration), and the filter was
collected for liquid scintillation counting. Aliquots of the
supernatant were measured for protein concentration by the Bradford
assay using gamma globulin as the standard. Enzymatic activity was
expressed in pmol CO2 · mg
protein-1 ·
h-1.
Polyamine Production
Polyamine formation was determined by incubating SMCs with
[3H]L-ornithine and monitoring the
intracellular formation of radiolabeled
putrescine.12 SMCs were plated onto 6-well plates
and incubated with [3H]L-ornithine
(20 µCi/mmol) for 8 hours. The reaction was stopped by removing the
radiolabel-containing media and washing the cells with ice-cold PBS (pH
7.4). Ice-cold Tris (20 mmol/L, pH 7.4) buffer containing Triton
X-100 (0.01%) was then added to the monolayer, and cells were scraped,
vortexed, and centrifuged at 10 000g for 1 minute.
Aliquots of the supernatant were spotted onto thin-layer
chromatography plates and developed in the solvent
system chloroform:methanol:ammonium hydroxide:water (1:4:2:1, by
volume). After drying, putrescine was detected by ninhydrin spray, and
[3H]putrescine was identified by
cochromatography with unlabeled putrescine, scraped,
and quantified by liquid scintillation counting.
mRNA Analysis
Total cellular RNA was obtained by the guanidine
isothiocyanate/CsCl procedure, and RNA concentration was determined by
absorbance spectrophotometry at 260 nm.29 CAT
mRNA levels were determined by solution hybridization/ribonuclease
protection analysis.12 30 In brief, total
RNA (15 µg) was hybridized with 5x105 cpm of
[32P]UTP-labeled antisense CAT and GAPDH
riboprobes (316 bp). The CAT-1 (195-bp) and CAT-2 (210-bp) antisense
RNA probes were prepared as described earlier.12
Samples were incubated in hybridization buffer (65 mmol/L sodium
citrate, 200 mmol/L sodium acetate, 0.5 mmol/L EDTA, and 55%
formamide) for 16 hours at 45°C, followed by digestion with
ribonuclease A (40 µg/mL) and ribonuclease T1 (2 µg/mL) at room
temperature for 30 minutes. Protected RNA was analyzed by
electrophoresis using 6% acrylamide/8 mol/L urea gel. The
gel was exposed overnight to x-ray film at -70°C in the presence of
intensifying screens. The size of the predicted
nucleotide-protected fragment was confirmed using a
32P-labeled RNA molecular weight ladder.
ODC mRNA levels were determined by Northern blotting. Total RNA (30
µg) was loaded on 1.2% gels containing 2.2 mol/L formaldehyde and
fractionated by electrophoresis. RNA was blot-transferred to Gene
Screen Plus membranes and prehybridized for 4 hours at 42°C in a
solution containing deionized formamide (40%), 2x SSC, 5x
Denhardt's reagent, SDS (2%), and denatured salmon sperm DNA (100
µg/mL). Membranes were hybridized overnight at 42°C in
prehybridization solution containing [32P]DNA
probes (1 to 4x105 cpm/mL) for ODC and GAPDH.
DNA probes were labeled with [-32P]dCTP by
random priming. After hybridization, membranes were washed twice with
0.1x SSC/0.1% SDS at 42°C for 20 minutes and then exposed to Kodak
X-Omat film at -70°C in the presence of intensifying screens.
For both ribonuclease protection assays and Northern blotting, relative mRNA levels were quantified by scanning densitometry (LKB 2222-020 Ultrascan XL laser densitometer) and normalized with respect to GAPDH mRNA.
SMC Proliferation
SMCs were seeded at a density of 2.0x104
cells per well in 12-well plates in serum (10%)–containing media.
After 24 hours, culture media were exchanged for serum-free media, and
cells were incubated for an additional 48 hours. SMCs were then treated
with thrombin in the presence or absence of DFMO. Media, with
appropriate additions, were replenished every second day. Cell number
determinations were performed after 4 days of treatment by dissociating
cells with trypsin (0.025%) and EDTA (1 mmol/L) and counting
cells in a calibrated Coulter Counter (model ZF, Coulter
Electronics).
Statistics
Results are expressed as the mean±SEM. Statistical
analysis was performed with the use of the Student 2-tailed
t test and ANOVA when >2 treatments were compared. Values
of P<0.05 were considered to be statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vascular SMCs expressed constitutive L-ornithine transport activity (422±28 pmol · mg protein-1 · 45 s-1) that was increased by thrombin in a concentration-dependent manner (Figure 1
). Time-course studies demonstrated that
thrombin (10 nmol/L) had a biphasic effect on L-ornithine
transport (Figure 2). Initially, thrombin
exposure inhibited the transport of L-ornithine, but by 6
hours of thrombin treatment, a significant rise in transport was
observed, and this was further increased after 24 hours of treatment.
The stimulatory effect by thrombin on L-ornithine transport
was mimicked by TRAP (Figure 3) and was
blocked by the thrombin inhibitor
hirudin31 (Figure 3). Hirudin failed to prevent
the TRAP-induced increase in L-ornithine uptake (Figure 3).
Incubation of SMCs with cycloheximide or actinomycin D blocked
thrombin-stimulated L-ornithine transport without affecting
basal uptake (Figure 4). A neutralizing
antibody directed against PDGF had no effect on thrombin-stimulated
L-ornithine transport (data not shown). Furthermore,
treatment of SMCs with trypsin or plasmin failed to stimulate
L-ornithine uptake (data not shown).
|
|
|
|
In subsequent kinetic studies, saturable uptake of radiolabeled
L-ornithine (5 to 500 µmol/L) was measured. As
evident from a representative Eadie-Hofstee plot
(Figure 5), high-affinity uptake of
L-ornithine by vascular SMCs was mediated by a single
carrier. Data from several experiments (n=5) indicated that this
transporter had a Michaelis constant (Km)
of 116.2±14.2 µmol/L and a maximum transport velocity
(Vmax) of 612±65 pmol · mg
protein-1 · 45
s-1. Pretreatment of vascular SMCs with thrombin
(10 nmol/L) for 24 hours significantly increased both the
Km (226.3±17.2 µmol/L,
P<0.05) and Vmax (1952±212 pmol
· mg protein-1 · 45
s-1, P<0.05) of the
L-ornithine transporter.
|
)
and in SMCs pretreated with thrombin (10 nmol/L for 24 hours) (
).
Transport velocity was plotted as a function of
velocity/L-ornithine concentration (µmol/L). Similar
findings were made in 4 separate experiments.
Treatment of vascular SMCs with thrombin for 8 hours stimulated the
expression of mRNA for both cationic amino acid transporters, CAT-1 and
CAT-2, in a concentration-dependent manner (Figure 6). Thrombin (10 nmol/L) induced an 4-
and 5-fold increase in the steady-state levels of CAT-1 and CAT-2 mRNA,
respectively. Incubation of SMCs with actinomycin D (2 µg/mL)
resulted in a rapid decay of CAT-1 (t1/2, 150
minutes) and CAT-2 (t1/2, 60 minutes) mRNA.
Thrombin had no effect on the stability of CAT-1 or CAT-2 message (data
not shown).
|
Incubation of vascular SMCs with thrombin also induced ODC activity.
Significant increases in enzyme activity were evident 4 hours after
thrombin (10 nmol/L) addition, reached maximum activity at 8 hours
(20-fold), and then declined toward basal levels by 24 hours (Figure 7A). Increases in ODC activity were
dependent on the concentration of thrombin (Figure 7B) and were
mimicked by TRAP (Figure 8). In addition,
hirudin selectively reversed the thrombin-mediated increase in ODC
activity but had no effect on the TRAP-induced rise in activity (Figure 8). Treatment of SMC with cycloheximide or actinomycin D abolished the
thrombin-stimulated increase in ODC activity (Figure 9).
|
|
|
Untreated control SMCs did not express ODC message; however, treatment
of SMCs with thrombin induced, in a concentration-dependent fashion,
the expression of 2 distinct ODC transcripts of 2.6 and 2.2 kb,
respectively (Figure 10). Thrombin (10
nmol/L)-stimulated an 12-fold increase in the larger (2.6-kb)
transcript, whereas the smaller (2.2-kb) transcript increased
10.5-fold.
|
Treatment of vascular SMCs with thrombin increased the capacity of SMCs
to generate the polyamine putrescine from extracellular
L-ornithine in a concentration-dependent manner (Figure 11A). The stimulatory effect of
thrombin on putrescine synthesis was inhibited by the cationic amino
acid transport inhibitor
NG-methyl-L-arginine
(L-NMA, 10 mmol/L)20 and by the
selective ODC inhibitor DFMO (2
mmol/L)32 (Figure 11B). In addition, DFMO (2
mmol/L) blocked the proliferative effect of thrombin (10 nmol/L) on
vascular SMCs (Figure 12).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The present study demonstrates that thrombin stimulates polyamine synthesis in vascular SMCs and that polyamines contribute to the proliferative action of thrombin. Thrombin induces polyamine production by modulating the expression of the genes that regulate the transport and metabolism of L-ornithine. In particular, thrombin increases the transcellular transport of L-ornithine and its intracellular metabolism to polyamines by stimulating the expression of the genes for both CAT and ODC. These thrombin effects are specific receptor-mediated responses, since they are reversed by hirudin and are mimicked by a thrombin receptor–activating peptide. In addition, other serine proteases such as trypsin and plasmin have no effect on L-ornithine transport.
Treatment of vascular SMCs with thrombin stimulates the transport of
L-ornithine in both a time- and concentration-dependent
manner. Kinetic experiments indicate that high-affinity
(Km, 120 µmol/L)
L-ornithine transport is mediated by a single carrier
system and that thrombin increases both the Vmax
and Km of this transport system. These
kinetic data suggest that the thrombin-induced decrease in
L-ornithine uptake observed at early time points likely
arises from a thrombin-mediated decrease in affinity of the
transporter. In contrast, the increase in L-ornithine
transport observed at later time points may result from the de novo
expression of additional transport proteins. In accordance with this,
we found that cycloheximide blocks thrombin-induced transport.
Interestingly, incubation of SMCs with cycloheximide for 24 hours had
no effect on basal transport activity, indicating that CAT proteins
have a low rate of turnover.
Studies in our laboratory and others have shown that high-affinity transport of cationic amino acids by vascular SMCs is mediated by CAT-1 and CAT-2.12 33 The present study demonstrates that thrombin stimulates a comparable induction of CAT-1 and CAT-2 mRNA expression. Although the molecular mechanism by which thrombin induces CAT gene expression is not known, it likely involves the transcriptional activation of the CAT genes, since the transcriptional inhibitor actinomycin D blocks this effect. Moreover, thrombin has no effect on the stability of CAT mRNA.
The coexpression of both CAT-1 and CAT-2 mRNA in vascular SMCs after thrombin treatment is also observed after the administration of PDGF or angiotensin and suggests a general mechanism by which growth factors increase intracellular L-ornithine levels.12 33 Interestingly, thrombin induces PDGF synthesis from SMCs,6 7 raising the possibility that the thrombin effect is secondary to PDGF release. Although neutralizing antibodies to PDGF fail to modulate thrombin-mediated increases in L-ornithine uptake, SMC-derived PDGF may exert its effect in an intracrine manner, which would be unaffected by neutralizing antibodies.
In addition to stimulating transcellular L-ornithine transport, thrombin stimulates the intracellular metabolism of L-ornithine to polyamines in vascular SMCs. Thrombin induces ODC activity in a concentration- and time-dependent manner. Increases in ODC activity are paralleled by increases in ODC mRNA, suggesting that thrombin stimulates ODC gene transcription. The capacity of the transcriptional inhibitor, actinomycin D, to inhibit thrombin-stimulated ODC activity is consistent with this notion. The induction of 2 ODC mRNA species in vascular SMCs is also in agreement with previous studies using different cells and/or stimuli.18 34 35 The 2 ODC mRNA species appear to arise from the alternative use of 2 different polyadenylation signals.36 37
The coinduction of CAT and ODC proteins by thrombin may provide a mechanism by which increased levels of substrate (L-ornithine) are provided to SMCs during activation of the ODC enzyme. In this respect, treatment of vascular SMCs with thrombin results in a prominent increase in the capacity of SMCs to generate putrescine. This thrombin-mediated effect is blocked by the cationic amino acid transport inhibitor L-NMA and by the selective ODC inhibitor DFMO, indicating that both the transcellular transport of L-ornithine and intracellular ODC activity are limiting factors that regulate the capacity of thrombin to generate polyamines in vascular SMCs. Interestingly, L-ornithine uptake is dissociated from polyamine synthesis at later time points. Whereas thrombin stimulates a transient elevation in ODC activity that gradually returns toward basal levels after 24 hours of exposure, L-ornithine transport activity progressively increases during this time. The increase in transport activity at this time may serve to provide the necessary amino acids required for the synthesis of new proteins during cell growth. In support of this proposal, enhanced CAT gene expression has also been demonstrated in numerous proliferating cells, including hepatocytes, lymphocytes, and various tumor cells.38 39
The capacity of thrombin to regulate cationic amino acid transport and metabolism in vascular SMCs may be of pathophysiological importance. After local injury of the blood vessel wall, thrombin is generated from its circulating zymogen prothrombin. Thrombin would augment L-ornithine uptake and metabolism, resulting in cellular polyamine production and SMC proliferation. In addition, our earlier studies40 41 demonstrating that thrombin inhibits inducible NO synthase expression in vascular SMCs would further promote intimal proliferation by inhibiting the synthesis of the antiproliferative molecule NO from the cationic amino acid L-arginine.42 Thus, the combined ability of thrombin to stimulate polyamine synthesis and inhibit NO generation may contribute to its SMC proliferative action at sites of vascular injury.
In conclusion, these studies demonstrate that thrombin stimulates SMC polyamine biosynthesis by coordinately inducing the expression of the genes for both CAT and ODC. In addition, they show that thrombin-stimulated SMC proliferation is dependent on polyamine synthesis. The capacity of thrombin to upregulate L-ornithine transport and to direct its metabolism to polyamines may contribute to postangioplasty restenosis and atherosclerotic lesion formation.
|
Acknowledgments |
|---|
This study was supported in part by National Heart, Lung, and Blood Institute grant HL-36045, the Veterans Affairs Merit Review Board, and a grant from the American Heart Association.
Received December 15, 1997; accepted April 27, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol. 1989;135:499–508.[Abstract]
2. Walz DA, Anderson GF, Ciaglowski RE, Aiken M, Fenton JW II. Thrombin-elicited contractile response of aortic smooth muscle. Proc Soc Exp Biol Med. 1985;180:518–526.[Medline] [Order article via Infotrieve]
3.
Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER,
Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing
restenosis after balloon angioplasty of atherosclerotic femoral
arteries in rabbits. Circulation. 1991;84:232–243.
4. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Caughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically active receptor. J Clin Invest. 1993;91:94–98.
5. Herbert JM, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor: effect of heparin. FEBS Lett. 1992;301:155–158.[Medline] [Order article via Infotrieve]
6. Kanthou C, Parry G, Wijelath E, Kakkar DV, Demoliou-Mason C. Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. FEBS Lett. 1992;314:143–148.[Medline] [Order article via Infotrieve]
7.
Stouffer GA, Sarembock IJ, McNamara CA, Gimple LW,
Owens GK. Thrombin-induced mitogenesis of vascular SMC is partially
mediated by autocrine production of PDGF-AA. Am J
Physiol. 1993;265:C806–C811.
8.
Ross RR, Glomset J, Kariya B, Harker L. A platelet
dependent serum factor that stimulates the proliferation of
arterial smooth muscle cells in vitro. Proc Natl Acad
Sci U S A. 1974;71:1207–1211.
9.
Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF.
-Thrombin induces the release of platelet-derived growth
factor-like molecule(s) by cultured human endothelial
cells. J Cell Biol. 1986;103:1129–1133.
10. Thyberg J, Fredholm BB. Induction of ornithine decarboxylase activity and putrescine synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Exp Cell Res. 1987;170:160–169.[Medline] [Order article via Infotrieve]
11. Nishida K, Abiko T, Ishihara M, Tomikawa M. Arterial injury-induced smooth muscle cell proliferation in rats is accompanied by increase in polyamine synthesis and level. Atherosclerosis. 1990;83:119–125.[Medline] [Order article via Infotrieve]
12.
Durante W, Liao L, Iftikhar I, Cheng K, Shafer AI.
Platelet-derived growth factor regulates vascular smooth muscle
cell proliferation by inducing cationic amino acid transporter gene
expression. J Biol Chem. 1996;271:11838–11843.
13. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem. 1984;53:749–790.[Medline] [Order article via Infotrieve]
14.
Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin
regulates smooth muscle S phase entry in the injured rat carotid
artery. Circ Res. 1987;61:296–300.
15. Endean ED, Kispert JF, Martin KW, O'Connor W. Intimal hyperplasia is reduced by ornithine decarboxylase inhibition. J Surg Res. 1991;50:634–637.[Medline] [Order article via Infotrieve]
16. Wu VS, Byus CV. A role for ornithine in the regulation of putrescine accumulation and ornithine decarboxylase activity. Biochim Biophys Acta. 1984;804:89–99.[Medline] [Order article via Infotrieve]
17. Gonzalez GG, Byus CV. The level of substrate ornithine can alter polyamine-dependent DNA synthesis following phorbol ester stimulation of cultured hepatoma cells. J Cell Physiol. 1991;149:9–19.[Medline] [Order article via Infotrieve]
18.
Durante W, Liao L, Peyton KJ, Schafer AI.
Lysophosphatidylcholine regulates cationic amino acid transport and
metabolism in vascular smooth muscle cells: role in
polyamine biosynthesis. J Biol Chem. 1997;272:30154–30159.
19. Low BC, Ross IK, Grigor MR. Characterization of system L and system y+ amino acid transport activity in cultured vascular smooth muscle cells. J Cell Physiol. 1993;156:626–634.[Medline] [Order article via Infotrieve]
20.
Durante W, Liao L, Schafer AI. Differential regulation
of L-arginine transport and inducible NOS in cultured vascular smooth
muscle cells. Am J Physiol. 1995;268:H1158–H1164.
21. White MF. The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1985;822:355–374.[Medline] [Order article via Infotrieve]
22. Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell. 1989;57:659–634.[Medline] [Order article via Infotrieve]
23.
MacLeod CL, Finley KD, Kakuda DK, Kozak DK, Wilkinson
MF. Activated T cells express a novel gene on chromosome 8 that
is closely related to the murine ecotropic retroviral receptor.
Mol Cell Biol. 1990;10:3663–3674.
24.
Closs EI, Lyons CR, Kelly C, Cunningham JM.
Characterization of the third member of the MCAT family of cationic
amino acid transporters: identification of a domain that determines the
transport properties of the MCAT proteins. J Biol Chem. 1993;268:20796–20800.
25.
Closs EI, Albritton LM, Kim JW, Cunningham JM.
Identification of a low affinity, high capacity transporter of cationic
amino acids in mouse liver. J Biol Chem. 1993;268:7538–7544.
26.
Durante W, Schini VB, Catovksy S, Kroll MH, Vanhoutte
PM, Schafer AI. Plasmin potentiates the induction of nitric oxide
synthase by interleukin-1ß in vascular smooth muscle.
Am J Physiol. 1993;264:H617–H623.
27. Smith PK, Krohn RI, Hermanson GI, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76–85.[Medline] [Order article via Infotrieve]
28.
Russell DH, Snyder SH. Amine synthesis in regenerating
rat liver: extremely rapid turnover of ornithine decarboxylase.
Mol Pharmacol. 1969;5:253–262.
29. Chirgwin JM, Przbyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294–5299.[Medline] [Order article via Infotrieve]
30.
Durante W, Liao L, Schafer AI. Selective induction of a
cationic amino acid transporter by tumor necrosis factor- in
vascular endothelium. Proc Assoc Am
Physicians. 1996;108:356–361.[Medline]
[Order article via Infotrieve]
31. Chang JY. The function of hirudin, a thrombin specific inhibitor. FEBS Lett. 1983;164:307–313.[Medline] [Order article via Infotrieve]
32.
Pegg A. Polyamine metabolism and its
importance in neoplastic growth and as a target for chemotherapy.
Cancer Res. 1988;48:759–774.
33.
Low BC, Grigor MR. Angiotensin II
stimulates system y+ and cationic amino acid
transporter gene expression in cultured vascular smooth muscle cells.
J Biol Chem. 1995;270:27577–27583.
34.
Gilmour SK, Avdalovic N, Madara T, O'Brien TG.
Induction of ornithine decarboxylase by
12-O-tetradecanoylphorbol 13-acetate in hamster
fibroblasts. J Biol Chem. 1985;260:16439–16444.
35.
Berger FG, Szymanski P, Read E, Watson G.
Androgen-regulated ornithine decarboxylase mRNA's of mouse kidney.
J Biol Chem. 1985;259:7941–7946.
36.
Hickok NJ, Seppanen PJ, Kontula KK, Janne PA. Two
ornithine decarboxylase mRNA species in mouse kidney arise from size
heterogeneity at their 3' termini. Proc Natl Acad
Sci U S A. 1986;83:594–598.
37.
Wen L, Huang J-K, Blackshear PJ. Rat ornithine
decarboxylase gene: nucleotide sequence, potential
regulatory elements and comparison to the mouse gene. J Biol
Chem. 1989;264:9016–9021.
38.
Yoshimoto T, Yoshimoto E, Meruelo D. Enhanced gene
expression of the murine ectropic retroviral receptor and its human
homolog in proliferating cells. J Virol. 1992;66:4377–4381.
39.
Wu JY, Robinson D, Kung HJ, Hatzoglou M. Hormonal
regulation of the gene for the type C ecotropic retrovirus receptor in
rat liver cells. J Virol. 1994;68:1615–1623.
40.
Schini VB, Catovsky S, Durante W, Scott-Burden T,
Schafer AI, Vanhoutte PM. Thrombin inhibits the induction of nitric
oxide synthase in cultured vascular smooth muscle cells. Am
J Physiol. 1993;264:H611–H616.
41. Durante W, Kroll MH, Orloff GJ, Cunningham JM, Scott-Burden T, Vanhoutte PM, Schafer AI. Regulation of interleukin-1ß-stimulated inducible nitric oxide synthase expression in cultured vascular smooth muscle cells by hemostatic proteins. Biochem Pharmacol. 1996;51:847–853.[Medline] [Order article via Infotrieve]
42. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1779.
This article has been cited by other articles:
 |
|
 |
|
  K. J. Peyton, D. Ensenat, M. A. Azam, A. N. Keswani, S. Kannan, X.-m. Liu, H. Wang, D. A. Tulis, and W. Durante Arginase Promotes Neointima Formation in Rat Injured Carotid Arteries Arterioscler. Thromb. Vasc. Biol., April 1, 2009; 29(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Wei, Y. Yang, G. Wu, and L. J. Ignarro IL-4 and IL-13 upregulate ornithine decarboxylase expression by PI3K and MAP kinase pathways in vascular smooth muscle cells Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1198 - C1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dumont, M. Zureik, C. Bauters, M.-C. Grupposo, D. Cottel, M. Montaye, M. Hamon, P. Ducimetiere, P. Amouyel, and T. Brousseau Association of OAZ1 Gene Polymorphisms With Subclinical and Clinical Vascular Events Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2120 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dumont, M. Zureik, D. Cottel, M. Montaye, P. Ducimetiere, P. Amouyel, and T. Brousseau Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness J. Med. Genet., August 1, 2007; 44(8): 526 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaneko, E. Okuda-Ashitaka, A. Ando, K. Nishimura, K. Igarashi, M. Maeda, K. Furuta, M. Suzuki, M. Matsumura, and S. Ito Polyamines upregulate the mRNA expression of cationic amino acid transporter-1 in human retinal pigment epithelial cells Am J Physiol Cell Physiol, August 1, 2007; 293(2): C729 - C737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Teupser, R. Burkhardt, W. Wilfert, I. Haffner, K. Nebendahl, and J. Thiery Identification of Macrophage Arginase I as a New Candidate Gene of Atherosclerosis Resistance Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Teixeira, M. L. Santaolaria, V. Meneu, and E. Alonso Dietary Arginine Slightly and Variably Affects Tissue Polyamine Levels in Male Swiss Albino Mice J. Nutr., December 1, 2002; 132(12): 3715 - 3720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Durante, L. Liao, S. V. Reyna, K. J. Peyton, and A. I. Schafer Transforming Growth Factor-{beta}1 Stimulates L-Arginine Transport and Metabolism in Vascular Smooth Muscle Cells : Role in Polyamine and Collagen Synthesis Circulation, February 27, 2001; 103(8): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Van Winkle Amino Acid Transport Regulation and Early Embryo Development Biol Reprod, January 1, 2001; 64(1): 1 - 12. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. DURANTE, L. LIAO, S. V. REYNA, K. J. PEYTON, and A. I. SCHAFER Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle FASEB J, September 1, 2000; 14(12): 1775 - 1783. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Wu, B. Cholewa, and D. L. Mattson Characterization of L-arginine transporters in rat renal inner medullary collecting duct Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2000; 278(6): R1506 - R1512. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||